SRC and cancer: Cancer cell line HCT116 was treated with trametinib (5μM) alone, or in combination with one of the following agents: ruxolitinib (2.5μM, JAK2 inhibitor), tofacitinib (2.5μM, JAK3 inhibitor) or KX2-391 (2.5μM, Src inhibitor).